Adherence to Anti-Tuberculosis Treatment Among Pediatric Patients at Nekemte Specialized Hospital, Western Ethiopia

Figures & data

Table 1 Socio-Demographic Characteristic of the Pediatrics TB Patients Attending NSH, 2019

Variables		Frequency (n)	Percent (%)
Age (years)	0–5	43	21.3
	6–10	40	19.8
	11–15	119	58.9
Gender	Male	120	59.4
	Female	82	40.6
Weight (kg)	<25	54	26.7
	≥25	148	73.3
Residence	Urban	76	37.6
	Rural	126	62.4

Table 2 Disease and Clinical Related Characteristics of TB Pediatrics Patients Attending NSH, 2019

Variables		Frequency (n)	Percent (%)
Side effect	Yes	126	62.4
	No	76	37.6
Type of side effect (n=126)	NVD	55	27.2
	Changed eye color	27	13.4
	Other	44	21.8
Disease classification	PTB-SM+	24	11.9
	PTB-SM-	12	5.9
	EPTB	166	82.2
Pre-treatment Smear result	Smear positive	64	31.7
	Smear negative	17	8.4
	Not done	121	59.9
Treatment phase	Intensive	174	86.1
	Continuous	28	13.9
HIV status	Positive	10	5
	Negative	192	95
Medicines besides TB treatment	Yes	15	7.4
	No	187	92.6
	Total	202	100
Medicine was taking for (n=15)	HAART	10	66.7
	Multivitamins	5	33.3

Abbreviations: HAART, highly active ant-retroviral therapy; NVD, nausea, vomiting, and diarrhea; EPTB, extrapulmonary tuberculosis; PTB-SM+, smear positive pulmonary tuberculosis; PTB-SM-, smear negative pulmonary tuberculosis.

Table 3 Bivariate and Multivariate Analysis of Factors Associated with TB Treatment Adherence Among Pediatrics Patients Attending NSH, 2019

Variables		Adhered	Not Adhered	COR (95% CI)	AOR (95% CI)	p-value
Age (age)	0–5	39 (90.7%)	4 (9.3%)	4.94 (1.65–14.78)*	5.96 (1.81–19.6)**	0.003
	6–10	30 (75%)	10 (25%)	1.52 (0.67–3.42)	1.75 (0.7–4.36)	0.23
	11–15	79 (66.4%)	40 (33.6%)	1	1
Sex	Male	81 (67.5%)	39 (32.5%)	1	1
	Female	67 (81.7%)	15 (18.3%)	2.15 (1.09–4.24)*	3.3 (1.52–7.2)**	0.003
Weight (kg)	≥25	45 (83.3%)	9 (16.7%)	2.18 (0.98–4.85)*	0.74 (0.19–2.84)	0.6
	<25	103 (69.6%)	45 (30.4%)	1	1
Residence	Urban	52 (68.4%)	24 (31.6%)	3.29 (0.78–2.78)*	3.73 (1.67–8.36)**	0.001
	Rural	50 (39.7%)	76 (60.3%)	1	1
Treatment duration (months)	≤2	130 (74.7%)	44 (25.3%)	1.64 (0.7–3.82)*
	>2	18 (64.3%)	10 (35.7%)	1
Treatment phase	Intensive	114 (91.2%)	60 (77.9%)	2.94 (0.93–8.24)
	Continuous	11 (7.3%)	17 (22.1%)	1
Taking other medication	Yes	10 (66.7%)	5 (33.3%)	1
	No	138 (73.8%)	49 (26.2%)	1.41 (0.46–4.32)*
Experienced side effects	Yes	81 (81%)	45 (19%)	1
	No	46 (60.5%)	30 (39.5%)	2.76 (1.46–5.25)*	2.87 (1.41–5.81)**	0.013

Notes: *Shows significant at p-value 0.25, **Shows statistically significant at p-value 0.05.

Abbreviations: AOR, adjusted odds ratio; COR, crude odds ratio.